ABON is mainly engaged in research and development of IVD products with a registered capital of $22 million. ABON has been registered with the U. S. FDA as a medical device establishment and obtained Euro CE certification. Our leading products include women’s health, infectious disease, drugs of abuse, oncology, cardiovascular and respiratory.